HOB Biotech Group Corp Ltd - Asset Resilience Ratio
HOB Biotech Group Corp Ltd (688656) has an Asset Resilience Ratio of 2.62% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 688656 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2022)
This chart shows how HOB Biotech Group Corp Ltd's Asset Resilience Ratio has changed over time. See HOB Biotech Group Corp Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down HOB Biotech Group Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HOB Biotech Group Corp Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥25.01 Million | 2.62% |
| Total Liquid Assets | CN¥25.01 Million | 2.62% |
Asset Resilience Insights
- Limited Liquidity: HOB Biotech Group Corp Ltd maintains only 2.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
HOB Biotech Group Corp Ltd Industry Peers by Asset Resilience Ratio
Compare HOB Biotech Group Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 9.40% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Ok Biotech Co Ltd
TW:4155 |
Medical Devices | 0.32% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Annual Asset Resilience Ratio for HOB Biotech Group Corp Ltd (2021–2022)
The table below shows the annual Asset Resilience Ratio data for HOB Biotech Group Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 14.32% | CN¥135.23 Million ≈ $19.79 Million |
CN¥944.56 Million ≈ $138.22 Million |
+13.74pp |
| 2021-12-31 | 0.58% | CN¥5.01 Million ≈ $733.28K |
CN¥863.92 Million ≈ $126.42 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, Ch… Read more